MEDIUM confidence: 100% data completeness, but the composite (53) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Not enough return history to estimate factor exposures — 26 of 36 months required. This stock is too recently listed (or has too short a price history) for a reliable Fama-French regression.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $92 avg across 11 analysts.
Buy-rated share 97% → 100% over ~3 months (+3pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $-0.03 | $0.16 | +637.5% |
| Mar 2026 | $-0.11 | $0.04 | +136.7% |
| Dec 2025 | $-0.17 | $0.10 | +158.9% |
| Sep 2025 | $-0.34 | $-0.03 | +91.1% |
| Jun 2025 | $-0.32 | $-0.15 | +53.3% |
| Mar 2025 | $-0.39 | $-0.18 | +53.7% |
| Dec 2024 | $-0.40 | $-0.21 | +47.5% |
| Sep 2024 | $-0.49 | $-0.40 | +17.7% |
| Metric (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $506M— | $600M+18.5% | $628M+4.7% | $887M+41.2% | $1.3B+48.5% |
| EPS (dil.) | $-1.45— | $-1.58n/m | $-2.01n/m | $-7.48n/m | $-1.78n/m |
| Free Cash Flow | -$103M— | -$15Mn/m | -$17Mn/m | $31Mn/m | $253M+708.1% |
| Gross Margin | 53.3% | 53.4%+0.1pp | 62.1%+8.7pp | 70.0%+8.0pp | 80.1%+10.1pp |
| Operating Margin | -49.4% | -43.6%+5.7pp | -48.8%-5.2pp | -127.9%-79.1pp | -26.2%+101.7pp |
| Net Margin | -50.3% | -46.3%+4.0pp | -56.4%-10.1pp | -130.3%-73.9pp | -26.5%+103.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 18.7%/yr (revenue basis).
Base free cash flow $89M (avg FY2024–FY2026; latest year $253M) · equity value $20.9B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$11.2M over 180 days (0 open-market buys, 48 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 53 for RBRK indicates a neutral outlook, driven by strong growth and momentum scores, which are offset by low value and mixed profitability metrics. The stock's high revenue growth of 48.5% and EPS growth of 76.2% contribute to its strong growth score, while its 12-month return of 15.5% and 3-month return of 71.6% drive its momentum score. Notably, the stock trades at a premium, with a P/E of -69.7 and EV/EBITDA of -101.5, indicating a potential overvaluation. The long-term and short-term scores diverge, with the short-term score being 12 points higher, suggesting a recent surge in momentum.